Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines

SBTMO/SOPOBE Guidelines: Pediatric AML

Authors

  • Ana Luiza de Melo Rodrigues Department of Pediatric Oncology and Bone Marrow Transplant, Hospital Erastinho, Curitiba – PR, Brazil, Department of Internal Medicine/Hematology, Federal University of Paraná (UFPR), Curitiba – PR, Brazil
  • Victor Gottardello Zecchin
  • Maria Lúcia de Martino Lee Department of Pediatric Oncology and Bone Marrow Transplant, Hospital Beneficência Portuguesa, São Paulo – SP, Brazil
  • Antonella Adriana Zanette Department of Pediatric Oncology and Bone Marrow Transplant, Hospital Erastinho, Curitiba – PR, Brazil,
  • Adriana Seber Department of Pediatric Oncology and Bone Marrow Transplant, Hospital Samaritano, São Paulo – SP, Brazil
  • Raul Corrêa Ribeiro Department of Oncology and Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis - TN, USA

DOI:

https://doi.org/10.46765/2675-374X.2021v2n4p139

Keywords:

Hematopoietic Stem Cell Transplantation, Pediatric Acute Myeloid Leukemia, Clinical Guidelines

Abstract

Acute myeloid leukemia (AML) represents 15%–20% of acute leukemias in children, and the risk of treatment failure is based on genetic risk and response to therapy1-4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. The best therapeutic results are achieved by integrating intensive chemotherapy, optimal supportive care, and hematopoietic stem cell transplant (HSCT) adapted to each patient’s risk of relapse6–9. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML to provide evidence-based guidance for the appropriate management of this disease.

Author Biography

Victor Gottardello Zecchin

Department of Pediatric Oncology and Bone Marrow Transplant, Hospital Beneficência Portuguesa, São Paulo – SP, Brazil

Downloads

Published

11/30/2021

How to Cite

de Melo Rodrigues, A. L., Victor Gottardello Zecchin, Maria Lúcia de Martino Lee, Antonella Adriana Zanette, Adriana Seber, & Raul Corrêa Ribeiro. (2021). Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines: SBTMO/SOPOBE Guidelines: Pediatric AML. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(4), 139. https://doi.org/10.46765/2675-374X.2021v2n4p139

Issue

Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2021 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)